IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares will be issued at HK$20.10 per share—the same price as the initial offering—generating net proceeds of approximately HK$119.50 million after fees and expenses.

Following the exercise, total issued share capital will rise to 282.46 million shares, up from 276.17 million. Of this, public H-share float will expand from 41.98 million shares (15.20% of total share capital) to 48.27 million shares (17.09%), while the 234.19 million converted H shares remain unchanged. The transaction keeps the company in compliance with the Hong Kong Stock Exchange’s public-float requirement.

The newly issued over-allotment shares are slated to begin trading on the Main Board of the Stock Exchange at 9:00 a.m. on 10 June 2026.

Management stated that the incremental proceeds will be allocated on a pro-rata basis according to the “Future Plans and Use of Proceeds” outlined in the IPO prospectus.